Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1668 - Phase 3 study of avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC)


09 Oct 2016


Poster display


Robert Motzer


Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373


R.J. Motzer1, T.K. Choueiri2, J. Larkin3, L. Albiges4, J.B. Haanen5, M. Schmidinger6, M.B. Atkins7, M. Mariani8, M. Shnaidman9, A. Di Pietro8, B.I. Rini10

Author affiliations

  • 1 Department Of Medical Oncology, Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 2 The Lank Center For Genitourinary Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston/US
  • 3 Department Of Medical Oncology, Royal Marsden Hospital, London/GB
  • 4 Department Of Cancer Medicine, Gustave Roussy Cancer Campus, University of Paris Sud, Villejuif/FR
  • 5 Department Of Medical Oncology, The Netherlands Cancer Institute, 1066 CX - Amsterdam/NL
  • 6 Department Of Medicine I, Medical University of Vienna, A-1090   - Vienna  /AT
  • 7 Department Of Medical Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, 20057 - Washington/US
  • 8 Immuno-oncology, Pfizer Inc., 20152 - Milano/IT
  • 9 Immuno-oncology, Pfizer Inc., 10017 - New York/US
  • 10 Department Of Hematology And Oncology, Cleveland Clinic Taussig Cancer Institute, 44195 - Cleveland/US


Abstract 1668


Combining a checkpoint inhibitor with an anti-VEGF therapy is a promising treatment strategy for advanced renal cell carcinoma (aRCC). Avelumab* (MSB0010718C) is a fully human IgG1 anti-PD-L1 antibody with clinical activity in aRCC and other tumour types (eg, Apolo et al. ECC-ESMO 2015; Gulley et al. ECC-ESMO 2015). Axitinib is an anti-VEGF receptor tyrosine kinase inhibitor approved for second-line treatment of aRCC (Rini et al. Lancet 2011), which has also shown clinical activity as a first-line (1L) therapy (Hutson et al. Lancet Oncol 2013). An ongoing phase 1b study of avelumab + axitinib, administered at standard doses, showed tolerable safety and encouraging antitumour activity in treatment-naïve pts with aRCC. JAVELIN Renal 101, a randomized, multicenter, phase 3 study (NCT02684006) compares avelumab + axitinib vs sunitinib in treatment-naïve pts with aRCC.

Trial design

The primary objective is to demonstrate superiority of 1L avelumab + axitinib vs sunitinib monotherapy in prolonging progression-free survival (PFS). Eligibility criteria include: aRCC with a clear cell component, ECOG PS ≤1, no prior systemic therapy for advanced disease, and measurable disease per RECIST v1.1. Approximately 583 pts will be randomized (1:1) and stratified based on ECOG PS (0 vs 1) and region (US vs Canada/Europe vs rest of the world). Pts receive either avelumab 10 mg/kg IV Q2W + axitinib 5 mg orally BID continuously (cycle length 6 weeks) or sunitinib 50 mg orally once daily for 4 weeks followed by 2 weeks off. Treatment is discontinued for unacceptable toxicity or if any criteria for withdrawal are met. Pts may continue treatment beyond progression (RECIST v1.1) if investigator-assessed clinical benefit is achieved and treatment is well tolerated. PFS will be assessed by blinded independent central review. Secondary endpoints include overall survival, PFS by investigator assessment, objective response, duration of response, time to response, safety, tumour biomarker assessments, and patient-reported outcomes. Enrolment in this pivotal phase 3 trial began in March 2016. *Proposed INN.

Clinical trial identification


Legal entity responsible for the study



Pfizer Inc.


R.J. Motzer: Consulting or Advisory Role: Pfizer, Novartis, Eisai Inc. Research Funding: Exelixis, BMS, Novartis, Pfizer, Genentech/Roche. T. Choueiri: Consulting or advisory role: Pfizer, Bayer, Novartis, GSK, Merck, BMS, Roche, Eisai, Prometheus Labs Inc, Foundation Medicine Inc., Cerulean. Research funding: Pfizer, Novartis, Merck, Exelixis, Tracon, GSK, BMS, AstraZeneca, Peloton, Roche. L. Albiges: Consulting or Advisory Role: Novartis, Pfizer, Amgen, BMS, Bayer, Sanofi, and Cerulean. Research Funding: Novartis and Pfizer. J.B. Haanen: Consulting/Advisory Role: BMS, MSD, Roche, Pfizer, Novartis, Neon Institution Research Funding: BMS, MDS, GSK. M. Schmidinger: Honoraria for lectures or consultancy from Pfizer, Novartis, Roche, BMS, Exelixis, Astellas Travel grants from Roche and Pfizer M.B. Atkins: Consulting or Advisory Role: Merck, Pfizer, AstraZeneca, BMS, Eisai, Genentech, Novartis, X4, Acceleron, Peloton, and Nektar. M. Mariani, M. Shnaidman: Employee and Stockholder: Pfizer Inc. A. Di Pietro: Employment: Pfizer. B.I. Rini: Consulting or Advisory Role: Roche, BMS, Pfizer, Acceleron, Novartis, GSK. Research Funding: Pfizer, BMS, Acceleron, Immatics, Peloton. Travel, Accommodations, Expenses: Pfizer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings